Literature DB >> 23553510

Combination therapy in hypertension.

Manuel Gorostidi1, Alejandro de la Sierra.   

Abstract

Hypertension is recognized as a major risk factor for cardiovascular and renal diseases and represents the leading cause of mortality worldwide. In spite of proven benefits of hypertension treatment, blood pressure control rates are poor, even in high-income countries with virtually full-access to therapies. Nearly 75% of hypertensive patients do not achieve adequate control with monotherapy, thus needing combination treatment. Strategies to improve blood pressure control include the prompt shift from monotherapy to combination therapy, the initial treatment with a two-drug combination, and the use of fixed-dose combinations in a single pill. Currently, preferred combinations include a renin-angiotensin blocker, either an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker plus a calcium channel blocker or a diuretic. Some patients will also require a triple combination to achieve blood pressure control.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23553510     DOI: 10.1007/s12325-013-0020-9

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  9 in total

1.  Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.

Authors:  Santosh Kumar Puttrevu; Rachumallu Ramakrishna; Manisha Bhateria; Moon Jain; Kashif Hanif; Rabi Sankar Bhatta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

Review 2.  Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.

Authors:  Daniel Glicklich; William H Frishman
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

3.  Association of Thiazide Use in Patients with Hypertension with Overall Fracture Risk: A Population-Based Cohort Study.

Authors:  Cheng-Hsun Chuang; Shun-Fa Yang; Pei-Lun Liao; Jing-Yang Huang; Man-Yee Chan; Chao-Bin Yeh
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

4.  Effect of Olmesartan-Based Therapies on Therapeutic Indicators Obtained Through Out-of-Office Blood Pressure.

Authors:  Manuel Gorostidi
Journal:  Cardiol Ther       Date:  2015-06-13

Review 5.  Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill.

Authors:  M Lafeber; W Spiering; F L J Visseren; D E Grobbee
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 6.  Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.

Authors:  Stefano Omboni; Ettore Malacco; Claudio Napoli; Pietro Amedeo Modesti; Athanasios Manolis; Gianfranco Parati; Enrico Agabiti-Rosei; Claudio Borghi
Journal:  Adv Ther       Date:  2017-03-04       Impact factor: 3.845

7.  Efficacy evaluation of serum galectin-3 in hypertension complicated with diastolic dysfunction.

Authors:  Tianwei Dong; Hongbin Li; Shuang Wang; Weida Chen
Journal:  Exp Ther Med       Date:  2019-11-18       Impact factor: 2.447

8.  Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.

Authors:  Jack Ishak; Michael Rael; Henry Punzi; Alan Gradman; Lynn M Anderson; Mehul Patel; Sanjida Ali; William Ferguson; Joel Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-11-05       Impact factor: 3.738

9.  Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic.

Authors:  Chien-Te Ho; Ying-Chang Tung; Shing-Hsien Chou; Fu-Chih Hsiao; Yu-Sheng Lin; Chee-Jen Chang; Pao-Hsien Chu
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-10-30       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.